The drug development and commercialization sector is anxiously waiting to see what the U.S. Food and Drug Administration has in store for a program evaluating real-world evidence’s potential.
“We’ve known for certain this is coming at least since passage of the 21st Century Cures Act in 2016,” Syneos Health Senior Vice President of RWE Late Phase David Thompson says. “But the forces leading to this moment have been at work for years — decades.”
To read Thompson’s full write up on Clinical Leader, click here. (Subscription required)
